Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing ...

Adults with psoriatic arthritis saw early improvements in their symptoms and key health-related quality-of-life measures with ...

Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific ...

HONG KONG, Sep 17, 2025 - (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies ...

Number three, think about the definition of success ... is along the lines of the left to right that Brock had mentioned earlier in the presentation. We're bringing in data from a number of different ...

Imperative Care Announces Late-Breaking Data Presentation and Peer-Reviewed Publication from Pivotal Trial of Symphony Thrombectomy System in Patients with Acute Pulmonary Embolism SYMPHONY-PE ...

Montgomery County Public Schools (MCPS) plans to ask the county for $2.7 billion to address facility issues as part of its proposed six-year capital improvements program (CIP), Superintendent Thomas ...

Patients with COPD or interstitial lung disease who partook in a weekly online group singing program reported improved ...

High dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments at completion of 16-week induction period Interim data presented for patients who ...

Objective To characterise the use of the prostate specific antigen (PSA) test in primary care in England. Design Population ...

Avacta is slated to present the final Phase Ia dose escalation data for our lead program, faridoxorubicin. This will be at ESMO 2025 in Berlin, a little bit later next month in October of 2025. There, ...

CAMPBELL, Calif., September 17, 2025--(BUSINESS WIRE)--Imperative Care, Inc. today announced positive efficacy and safety results from the pivotal SYMPHONY-PE Trial (NCT06062329) evaluating the ...